MedTrace Logo

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

NCT00449956 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 474

Last updated 2017-06-20

Study results available
· View outcomes & findings →

Summary

The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.

Conditions

Interventions

DRUG

dorzolamide hydrochloride (+) timolol maleate

Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week

DRUG

Comparator: timolol maleate

timolol maleate 0.5%, 8-week

DRUG

Comparator: dorzolamide hydrochloride

dorzolamide hydrochloride 1%, 8-week

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-12
Primary Completion
2008-02-16
Completion
2008-02-16

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00449956 on ClinicalTrials.gov